Brief: GlycoMimetics Announces First Cohort Dosed In Human Phase 1a Study Of GMI-1687
06/09/2023 12:10
Sept 6 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS ANNOUNCES FIRST COHORT DOSED IN HUMAN PHASE
1A
STUDY OF GMI-1687
* GLYCOMIMETICS INC- INITIAL RESULTS EXPECTED BY END Q1 2024
Source text for Eikon: ID:nBw2gpwQna
Further company coverage: GLYC.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering